公众号 / 文章技术与安全神经MR

钆沉积病:新的风险管理威胁

Gadolinium Deposition Disease: A New Risk Management Threat.
PubMed 文献 · J Am Coll Radiol · 2019-11-27

钆基对比剂(GBCA)自约30年前引入以来广泛使用,美国多达30%的MRI使用GBCA,不良事件发生率总体较低。2016年钆沉积病(GDD)被描述后,尽管科学上未证实,相关诉讼和人身伤害广告大量出现。本文介绍GDD是什么、为何产生医疗法律风险,并提出基于现有数据优先使用钆特醇作为默认GBCA的风险缓解策略。

要点

  • GBCA相关不良事件发生率总体较低,但2016年GDD描述后医疗法律风险改变。
  • GDD科学上未证实,却已出现大量相关诉讼和人身伤害广告。
  • 作者基于现有数据推荐优先使用钆特醇作为MRI默认GBCA。

核心结论

  • 作者主张采用以减少推测GDD发展期间脑部钆残留为核心的风险缓解策略,并基于现有数据推荐优先使用钆特醇作为MRI默认GBCA。

研究设计与样本

  • 本文为风险管理层面的论述文章,未报告系统检索、样本量或研究中心数。

临床应用与阅片要点

  • 作者建议采用以减少推测GDD发展期间脑部钆残留为核心的风险缓解策略。
  • 作者基于现有数据推荐优先使用钆特醇作为MRI默认GBCA。

局限性

  • 原文称GDD科学上未证实(unproven scientifically)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Gadolinium-based contrast agents (GBCAs) have enjoyed wide use since their introduction some 30 years ago. Used in as many as 30% of MRIs performed in the United States, GBCAs have generally been associated with low rates of adverse events. However, the safety profile and attendant medicolegal liability associated with GBCAs changed in 2016 with the description of gadolinium deposition disease (GDD). Despite being unproven scientifically, a groundswell of GDD-related litigation and personal injury advertising targeting potential GDD patients has occurred. In this article, we describe what GDD is, why GDD has created medicolegal risk, and how this risk might be mitigated. This article advocates using a risk mitigation strategy focused on reducing brain gadolinium retention during the period of purported GDD development. As such, based on the currently available data, the authors recommend the preferential use of gadoteridol as the default GBCA for MRI imaging.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Harvey HB, Gowda V, Cheng G, et al. Gadolinium Deposition Disease: A New Risk Management Threat. J Am Coll Radiol. 2019. PMID: 31805251. doi:10.1016/j.jacr.2019.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。